tiprankstipranks
Advertisement
Advertisement

CRVS Stock Latest News

Corvus Pharmaceuticals Announces Board Changes and New Director
Company AnnouncementsCorvus Pharmaceuticals Announces Board Changes and New Director
12d ago
8K
CRVS
Apple upgraded, Qualcomm downgraded: Wall Street’s top analyst calls
PremiumThe Fly
Apple upgraded, Qualcomm downgraded: Wall Street’s top analyst calls
18d ago
SR
CLX
Corvus Pharmaceuticals initiated with a Buy at Goldman Sachs
PremiumThe Fly
Corvus Pharmaceuticals initiated with a Buy at Goldman Sachs
19d ago
CRVS
Corvus Pharmaceuticals Bets Big on Soquelitinib Pipeline
PremiumCompany Announcements
Corvus Pharmaceuticals Bets Big on Soquelitinib Pipeline
2M ago
CRVS
Corvus Pharmaceuticals Expands Equity Sales Capacity to $200 Million
PremiumCompany Announcements
Corvus Pharmaceuticals Expands Equity Sales Capacity to $200 Million
2M ago
8K
CRVS
Corvus Pharmaceuticals price target raised to $33 from $32 at Oppenheimer
PremiumThe FlyCorvus Pharmaceuticals price target raised to $33 from $32 at Oppenheimer
2M ago
CRVS
Corvus Pharmaceuticals files automatic mixed securities shelf
Premium
The Fly
Corvus Pharmaceuticals files automatic mixed securities shelf
2M ago
CRVS
Corvus Pharmaceuticals: Strengthened Cash Runway and Expanding Soquelitinib Pipeline Underpin Buy Rating and Attractive Risk‑Reward Profile
Premium
Ratings
Corvus Pharmaceuticals: Strengthened Cash Runway and Expanding Soquelitinib Pipeline Underpin Buy Rating and Attractive Risk‑Reward Profile
2M ago
CRVS
Corvus Pharmaceuticals reports Q4 EPS (15c), consensus (13c)
PremiumThe Fly
Corvus Pharmaceuticals reports Q4 EPS (15c), consensus (13c)
2M ago
CRVS
Corvus Pharmaceuticals options imply 7.9% move in share price post-earnings
PremiumThe Fly
Corvus Pharmaceuticals options imply 7.9% move in share price post-earnings
2M ago
CRVS
Corvus’ Soquelitinib Trial Completion Adds a New Catalyst in the Atopic Dermatitis Market
PremiumCompany Announcements
Corvus’ Soquelitinib Trial Completion Adds a New Catalyst in the Atopic Dermatitis Market
2M ago
CRVS
Corvus Advances Soquelitinib Into Phase 2 Eczema Trial: What Investors Should Watch
PremiumCompany Announcements
Corvus Advances Soquelitinib Into Phase 2 Eczema Trial: What Investors Should Watch
2M ago
CRVS
Corvus Pharmaceuticals options imply 5.5% move in share price post-earnings
PremiumThe FlyCorvus Pharmaceuticals options imply 5.5% move in share price post-earnings
2M ago
CRVS
CRVS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
CRVS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
2M ago
CRVS
3 ‘Strong Buy’ Biotech Stocks to Buy Now, 1/29/2026, According to Top Analysts
Premium
Market News
3 ‘Strong Buy’ Biotech Stocks to Buy Now, 1/29/2026, According to Top Analysts
3M ago
CRVS
NRIX
Corvus Pharmaceuticals price target raised to $30 from $20 at Mizuho
PremiumThe Fly
Corvus Pharmaceuticals price target raised to $30 from $20 at Mizuho
3M ago
CRVS
Mizuho biotech analysts hold an analyst/industry conference call
PremiumThe Fly
Mizuho biotech analysts hold an analyst/industry conference call
3M ago
APGE
CRVS
Corvus Pharmaceuticals Announces Major Underwritten Public Stock Offering
PremiumCompany Announcements
Corvus Pharmaceuticals Announces Major Underwritten Public Stock Offering
3M ago
8K
CRVS
Corvus Pharmaceuticals price target raised to $42 from $13 at Jefferies
PremiumThe Fly
Corvus Pharmaceuticals price target raised to $42 from $13 at Jefferies
3M ago
CRVS
Corvus Pharmaceuticals 7.9M share Secondary priced at $21.15
PremiumThe FlyCorvus Pharmaceuticals 7.9M share Secondary priced at $21.15
3M ago
CRVS
Corvus Pharmaceuticals price target raised to $32 from $15 at Oppenheimer
Premium
The Fly
Corvus Pharmaceuticals price target raised to $32 from $15 at Oppenheimer
3M ago
CRVS
Closing Bell Movers: Netflix down 5% after soft guidance
Premium
The Fly
Closing Bell Movers: Netflix down 5% after soft guidance
3M ago
HWC
OZK

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >